- A computer vision empowered rapid antigen test to avoid human errors.
- An end-to-end digitized screening solution delivers test-to-report time in around 15 minutes.
- The enterprise SaaS solution enables organizations to reopen with confidence.
TAIPEI, June 3, 2021 /PRNewswire/ — iXensor Co., Ltd. (6734.TWO), the pioneer of mobile health, announces that its PixoTest® POCT COVID-19 Antigen Test has received the CE-IVD mark. The PixoTest® POCT COVID-19 Antigen Test provides the end-to-end fully digitalized rapid screening solution to prevent further outbreaks.
iXensor’s PixoTest® solution comprises a palm-sized analyzer that reads test results accurately, a digital health pass App, an Admin App, and a HIPAA-grade health management web portal. The fully digitized testing and reporting design shortens the test-to-report time to 15 minutes. In addition to overcoming the lab testing limitations, the solution allows for scaling in large screening settings, thereby enabling business continuity and reopening.
Smartphone-powered accurate results in 15 minutes:
With the PixoTest® POCT Analyzer reading test results objectively, healthcare organizations and corporations can minimize the risks of having false-negative cases compared to rapid tests interpreted by human eyes.
Concurrent reporting and digital health pass issuance:
The analyzer transmits test results simultaneously to the PixoHealth Pass App users via an encrypted QR code. The digital health pass also records App users’ vaccination certificates, helping free movement in the upcoming summer holiday season.
Mobile health technology addresses fake test reports:
The PixoHealth Pass Admin App is designed for organizations to verify the authenticity of PixoTest® test results with one simple scan. The admin app protects organizations’ safety amidst the pandemic by validating the cheat-proof, encrypted results shown on PixoHealth Pass App.
Superior accuracy meets EU standard:
In the prospective clinical study completed in Brazil, the PixoTest® showed 95% sensitivity and 98% specificity of nasopharyngeal specimens for the ranges of 0 to 7 days since symptom onset (DSO). Another study in the USA examined the clinical performance of anterior nasal specimens among symptomatic patients, which reported 92.8% sensitivity and 100% specificity, respectively.
To address the soaring demand for self-administered COVID-19 rapid tests, Dr. Peter Fitzgerald, Chairman of iXensor and Emeritus Professor of Medicine School at Stanford University announces, "We are deploying iXensor’s core PixoTech® technology to develop the smartphone-based self-test that can perform COVID-19 testing and tracking, anywhere at any time. I believe having COVID-19 at-home test will drastically cut many transmission paths to stop the pandemic."
iXensor, the pioneer of mobile health, turns smartphones into lab-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System as the world’s first US FDA-approved smartphone camera-based blood test. Based on the PixoTech® platform, iXensor has ventured into at-home self-testing and clinical point-of-care diagnostics across infectious diseases, women’s health, and cardiovascular diseases.
Related Links :